AstraZeneca Backs FY26 Core EPS Growth Guidance
AstraZeneca backed its FY26 guidance for core EPS to rise by a low double-digit percentage.
Related stories
US Sentiment: Terrible Tech Earnings Leads to Flight to Safety of Bonds
H impact | EARNINGS | Oct 30, 2026, 12:52 PM UTC
TSX Futures Slip as Oil Rebound Renews Inflation Concerns
attack in the Strait of Hormuz underscored supply risks. Energy-driven inflation concerns have weighed on major banks since the start of the US-Iran war by raising the risk of inte
H impact | EARNINGS | Oct 30, 2026, 12:44 PM UTC
Federal Realty Q3 Core FFO Rises 5.6%; Raises 2026 Guidance
Federal Realty Investment Trust reported third-quarter Nareit and Core FFO of $163.0 million, or $1.87 per diluted share, versus $153.0 million, or $1.77 per diluted share, in Q3 2
M impact | EARNINGS | Oct 30, 2026, 12:44 PM UTC
ExxonMobil and Chevron Top Q3 Estimates on Higher Prices and Strong Output
Both oil majors reported better-than-expected quarterly results Friday, attributed to higher prices and strong output.
M impact | EARNINGS | Oct 30, 2026, 12:41 PM UTC
Intel Shares Slide as Weaker Q4 Outlook Overshadows Data Center Growth
Intel reported third-quarter sales of $16.5 billion and non-GAAP EPS of $0.52, then issued a weaker fourth-quarter outlook. A factory shutdown, PC weakness and supply constraints w
H impact | EARNINGS | Oct 30, 2026, 12:36 PM UTC
First Abu Dhabi Bank Pjsc earnings above expectations at 0.50 AED
First Abu Dhabi Bank Pjsc (NBAD) released earnings per share at 0.50 AED, compared to market expectations of 0.47 AED.
H impact | EARNINGS | Oct 30, 2026, 12:29 PM UTC